At Tachyon, we are developing innovative therapies that target known cancer-driving mechanisms while addressing a significant challenge in cancer therapeutics: the ability of cancers to develop therapy resistance. Identifying effective strategies to overcome drug-evading cell populations remains a key challenge. Our programs aim to create therapies with novel approaches to eradicate these cells by targeting fundamental tumorigenic mechanisms. Our initial focus is on KDM4, a key player in the epigenetic regulation of cancer stem cells. This target is crucial as KDM4 regulates gene transcription connected to various oncogenic drivers, mutations, and signaling pathways.